Alicyn Campbell is currently Head of Digital Health Oncology R&D at AstraZeneca, where she leads on the development of strategies designed to increase their evidence base and improve care, through intelligent use of emerging technologies.
Alicyn has over 12 years of experience in Health Outcomes Research. Prior to joining AstraZeneca she served as the Global Head of Patient Centered Outcomes Research at Genentech/Roche. In that capacity, she was responsible for leadership in the assessment of the patient experience and consulted widely with the FDA and international regulators.
She achieved the first ever novel FDA patient reported outcome data approved in label for Hycela and was also responsible for novel patient-reported efficacy data for Hemlibra. She is the Founder, Executive Sponsor and Co-chair of Industry PRO-CTCAE Working Group, recognised as part of the ‘Cancer Moonshot’ initiative by President Biden and is a frequent research collaborator to Friends of Cancer Research and LUNGevity.
She has also authored several significant scientific publications and presentations, the latest of which was published in The Lancet Oncology.
